Longevity Biomarkers: What to Test, What the Results Mean, and How to Track Progress

Measuring biological aging is conceptually appealing but practically complex. Most people know their chronological age but have no objective measure of how fast they are actually aging at the cellular and systemic level. Longevity biomarkers attempt to fill this gap — with varying degrees of success.

This guide covers what to test, what the results reliably tell you, and how to use longitudinal tracking to assess intervention impact.

Tier 1: High-Actionability Conventional Labs

These tests are widely available, low cost, clinically validated, and directly actionable. They should form the foundation of any longevity monitoring panel.

Glycemic and Metabolic Markers

HbA1c (Glycated Hemoglobin)

• Reflects average blood glucose over ~3 months
• Strong predictor of diabetes risk, cardiovascular disease, kidney disease, and cognitive decline
• Target: below 5.7% (non-diabetic range); 5.7-6.4% = prediabetes risk zone; action warranted above 5.5% in a longevity-focused protocol
• Frequency: annually (every 6 months if elevated or actively intervening)

Fasting Glucose

• Direct measurement of blood glucose after 8-12 hours of fasting
• Target: below 95 mg/dL (optimal longevity range is narrower than standard clinical ranges)
• Interpret with HbA1c — discordance can indicate postprandial glucose spikes despite normal fasting levels

Fasting Insulin

• Reflects insulin resistance even when glucose appears normal
• HOMA-IR (derived from fasting glucose × fasting insulin / 405) quantifies insulin resistance
• Target: HOMA-IR below 1.5; values above 2.5 indicate meaningful insulin resistance
• Often overlooked in standard labs — requires requesting specifically

Lipids and Cardiovascular Risk

Lipid Panel with Calculated LDL

• Total cholesterol, LDL-C, HDL-C, triglycerides
• LDL-C target depends on cardiovascular risk — for low-risk individuals, context matters more than a single cutoff
• Triglycerides below 100 mg/dL optimal; above 150 = elevated risk signal

ApoB (Apolipoprotein B)

• Better cardiovascular risk predictor than LDL-C because it counts all atherogenic particles
• Each ApoB molecule represents one LDL, VLDL, or IDL particle
• Target: below 80 mg/dL for low cardiovascular risk; below 60 mg/dL for very high-risk individuals
• Increasingly recommended over LDL-C for risk assessment; request specifically

Lp(a) (Lipoprotein a)

• Genetically determined cardiovascular risk factor; minimally modifiable by lifestyle
• Elevated Lp(a) (>50 mg/dL or >125 nmol/L) increases cardiovascular risk substantially
• Test once — it is stable across life and does not change significantly with interventions
• Important for risk stratification; emerging pharmacological options (PCSK9 inhibitors, specific Lp(a)-lowering agents in development)

Inflammation Markers

hsCRP (High-Sensitivity C-Reactive Protein)

• Marker of systemic low-grade inflammation
• Target: below 1.0 mg/L optimal; 1-3 mg/L = moderate risk; above 3 mg/L = elevated risk
• Highly responsive to lifestyle interventions: diet quality, sleep, stress, omega-3 supplementation all lower CRP
• Avoid testing when acutely ill (CRP rises dramatically with any infection/injury)

IL-6 (Interleukin-6)

• A primary driver of systemic inflammation in aging ("inflammaging")
• Less commonly ordered but more specific to chronic inflammatory activation than CRP
• Target: below 2.0 pg/mL; levels rise predictably with age, obesity, poor sleep, and sarcopenia

Fibrinogen

• Coagulation factor and acute-phase protein
• Elevated in chronic inflammation and cardiovascular risk contexts
• Target: 150-350 mg/dL; chronically elevated fibrinogen increases thrombotic risk

Organ Function

Kidney: eGFR and Creatinine

• eGFR (estimated glomerular filtration rate) from creatinine (or cystatin C, which is more accurate in older adults)
• eGFR above 90 = normal; 60-90 = mildly reduced; below 60 = CKD territory
• CKD accelerates cardiovascular and all-cause mortality

Liver: ALT, AST, GGT

• Elevated ALT/AST signals hepatocellular stress; fatty liver disease is underdiagnosed
• Elevated GGT (even in non-drinkers) is an independent cardiovascular and all-cause mortality risk factor
• Target: GGT below 25 U/L

Hormonal and Nutritional

Vitamin D (25-OH Vitamin D)

• Deficiency (below 20 ng/mL) is common (40%+ of adults) and associated with multiple adverse longevity outcomes
• Optimal range: 40-60 ng/mL; above 100 ng/mL is not necessary and may be harmful
• Easily corrected with supplementation; highly actionable

Thyroid (TSH, Free T4)

• Subclinical hypothyroidism affects 5-10% of older adults and reduces energy, cognition, and cardiovascular health
• TSH outside range 0.5-2.5 mIU/L warrants investigation

DHEA-S (Dehydroepiandrosterone sulfate)

• Precursor to sex hormones; declines reliably with age (one of the strongest age-related hormonal trajectories)
• Not routinely actionable in same way as other markers; useful as biological age context

Testosterone (Total + Free, in men)

• Testosterone declines approximately 1-2% per year from age 30
• Relevant for muscle mass, cognition, cardiovascular risk, and quality of life assessment
• Free testosterone (the bioavailable fraction) is more informative than total in older men

Tier 2: Emerging Longevity-Specific Tests

These tests measure biological aging more directly but have more limited clinical actionability currently.

Epigenetic Age Clocks

DNA methylation clocks estimate biological age by measuring methylation patterns at hundreds of CpG sites.

Generations of clocks:

• First generation (Horvath 2013, Hannum 2013): correlate with chronological age but less predictive of health outcomes
• Second generation (PhenoAge, GrimAge): calibrated against phenotypic health markers and mortality risk; better predictors of morbidity and death than first-generation clocks
• Third generation (DunedinPACE): measure rate of aging (how fast you are aging right now), not just current biological age

What they tell you:

• Biological age vs. chronological age discrepancy (being "older" or "younger" biologically)
• Pace of aging (DunedinPACE)
• Organ-specific aging patterns (emerging organoid clocks)

Key limitations:

• Cost: $300-500+ per test; testing companies vary significantly in quality
• Noise: substantial test-retest variability means single measurements are unreliable; need multiple measurements to detect real change
• Intervention sensitivity: whether these clocks respond to interventions reliably enough to guide decisions is actively debated
• Confounders: tissue source (blood vs. other), time of day, recent illness all affect results
• No causal validation: a "younger" epigenetic age does not prove better health — they are correlated, not the same thing

Current recommendation: informative for baseline orientation and longitudinal tracking over 1-2 year intervals; not yet sensitive enough to guide month-to-month intervention decisions.

Telomere Length

• Average leukocyte telomere length declines with age and correlates with aging-related disease risk
• Available via blood tests from several commercial providers
• High test-retest variability; population-level correlation with outcomes does not translate to individual clinical utility at current precision levels
• Not recommended as primary monitoring tool currently

Proteomic Aging Scores

Companies including SomaLogic (SomaScan) and Olink measure thousands of circulating proteins simultaneously. Some emerging tests (e.g., Trutility, Nightingale) derive aging scores from plasma proteomic profiles.

• Potentially higher sensitivity and organ-specificity than epigenetic clocks
• Early data promising but not yet validated across diverse populations
• Higher cost than epigenetic tests

Practical Monitoring Protocol

Annual baseline panel (foundation):

• Comprehensive metabolic panel (includes glucose, creatinine, liver enzymes)
• Lipid panel + ApoB + Lp(a) (Lp(a) once per lifetime if never measured)
• HbA1c + fasting insulin (HOMA-IR)
• hsCRP + IL-6
• 25-OH Vitamin D
• Thyroid (TSH)
• CBC with differential

Every 2-3 years (if stable):

• DEXA scan (bone density + body composition — measures lean mass and visceral fat)
• Carotid intima-media thickness (CIMT) if cardiovascular risk concern

Optional advanced:

• Epigenetic age clock: baseline + annual or biennial retesting
• ApoB, Lp(a): measured initially; Lp(a) stable for life

Interpreting Trends Over Single Values

Single measurements establish baselines. The value of longitudinal tracking is detecting directional change:

• A single hsCRP of 2.8 mg/L is elevated but does not tell you if it is rising or falling
• HbA1c at 5.6% moving to 5.8% over 18 months is a meaningful signal — act before it crosses diagnostic thresholds
• Declining eGFR (even within normal range) tracked annually can catch kidney function trajectory years before clinical CKD

Trend data over 2-5 years is more actionable than any single-point measurement.

Related pages: Cardiovascular Disease Risk, Metabolic Syndrome and Insulin Resistance, Chronic Low-Grade Inflammation, Vitamin D3, Omega-3 Fatty Acids, Blue Zone Diet Longevity Evidence

Evidence Limits and What We Still Need

• Optimal frequency for most biomarker testing in healthy adults is not established by RCT
• Epigenetic clocks need better test-retest reliability and clearer intervention sensitivity data before routine clinical use
• The mapping from biomarker improvement to hard longevity outcomes (mortality reduction) is correlational, not causal, for most markers
• Cost-effectiveness of comprehensive biomarker panels vs. standard clinical labs has not been evaluated rigorously
• Reference ranges used by most labs were established in clinical disease contexts; "optimal" longevity ranges may differ

Sources

1. Epigenetic aging clocks and longevity prediction overview: https://pubmed.ncbi.nlm.nih.gov/34508015/
2. ApoB as cardiovascular risk predictor vs. LDL-C: https://pubmed.ncbi.nlm.nih.gov/30853537/
3. hsCRP and cardiovascular risk stratification (JUPITER trial): https://pubmed.ncbi.nlm.nih.gov/18997196/
4. HOMA-IR as insulin resistance measure: https://pubmed.ncbi.nlm.nih.gov/9519411/
5. Lp(a) as cardiovascular risk factor review: https://pubmed.ncbi.nlm.nih.gov/30165586/